Physician profile
Wendell Wall
NPI 1639174105
$25,338.45
in general payments reported to CMS, 2019-2025
54 companies · $4,337 in 2025
The $4,337 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,064 · 2020: $2,509 · 2021: $4,502 · 2022: $4,009 · 2023: $3,890 · 2024: $4,028 · 2025: $4,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,209.72 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,660.76 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $2,526.25 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $2,088.24 | 2019-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $1,506.45 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Biohaven Pharmaceuticals, INC. | $1,430.82 | 2021 | |
| Lilly USA, LLC | $1,424.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,292.92 | 2019-2025 | Xifaxan, Relistor |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,290.44 | 2020-2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $1,165.51 | 2020-2025 | Zoryve, Seglentis, Livalo |
| Novo Nordisk INC | $1,133.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sunovion Pharmaceuticals INC. | $729.62 | 2019-2022 | |
| Pfizer INC. | $694.61 | 2020-2025 | |
| Allergan, INC. | $618.28 | 2019-2020 | |
| Lundbeck LLC | $568.27 | 2021-2025 | Rexulti |
| Corium, LLC | $533.62 | 2022-2025 | Azstarys |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendell Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.